Clinical Trial Update: A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and cohort-expansion study evaluating anti-CD27 (Varlilumab) with anti-PD-1 (Nivolumab) in advanced refractory solid tumors (Phase 1/Phase 2) …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Glioblastoma
• Ovarian Carcinoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Varlilumab (varlilumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed | Phase 1, Phase 2 | Status: COMPLETED